PDCD1 and melanoma: In melanoma patients, analysis of patient fecal microbiome samples indicated a higher diversity in bacteria and amount of Ruminococcaceae bacteria among those who responded to anti-PD-1 immunotherapy (Gopalakrishnan et al., 2018).